To our knowledge, this nomogram is the first model to predict long‐term 3‐ and 5‐year individual survival, combining tumor EGFR mutation status and treatment‐related factors in stage III NSCLC patients with CRT. This evidence concerns the gene EGFR and non-small cell lung carcinoma.